Amie Y. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amie Y. Lee has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
Bonnie N. Joe
University of California, San Francisco, Department of Radiology and Biomedical Imaging, USA
15 shared publicationsKimberly M. Ray
University of California, San Francisco, Department of Radiology and Biomedical Imaging, USA
9 shared publicationsElissa R. Price
University of California, San Francisco, Department of Radiology and Biomedical Imaging, USA
7 shared publicationsJessica H. Hayward
University of California, San Francisco, Department of Radiology and Biomedical Imaging, USA
7 shared publicationsJessica H Hayward
Department of Radiology and Biomedical Imaging, University of California San Francisco , San Francisco, CA
5 shared publications- Jessica H. Hayward
From the Department of Radiology and Biomedical Imaging, University of California San Francisco, 513 Parnassus Ave, S-261, San Francisco, CA 94143
5 shared publications
Latest Publications
- Open Access
- 30 August 2025
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 7 (6) , 653-663
Epinephrine-Containing Lidocaine and Hematoma Risk After Image-Guided Core-Needle Breast Biopsy
Objective: To evaluate the risk of symptomatic hematomas in patients receiving epinephrine-containing lidocaine compared with lidocaine alone after core-needle breast biopsies (CNBBs). The efficacy of epinephrine-containing lidocaine in reducing hematoma risk following image-guided CNBB remains unclear. Methods: A single-institution, retrospective review of all CNBBs performed during a 6-month period using lidocaine alone (September 1, 2022, to March 15, 2023) due to a national shortage of epinephrine-containing lidocaine and a 6-month period using epinephrine-containing lidocaine (April 1, 2023, to October 1, 2023). A nurse navigator contacted all patients postbiopsy to assess postprocedural complications, including symptomatic hematomas. Postprocedure mammograms were reviewed for detectable hematomas after 9-gauge and 12- to 14-gauge CNBBs. Logistic regression models evaluated the associations between epinephrine-containing lidocaine use and symptomatic and mammographically evident hematomas. Results: A total of 1157 CNBBs were performed in 967 patients; 619 received epinephrine-containing lidocaine and 538 received lidocaine alone. There were 11 (1.0%; 11/1157) symptomatic hematomas, 10 of which occurred following 9-gauge CNBBs (6 with stereotactic/tomosynthesis guidance and 4 with MRI guidance). There was no significant difference in the occurrence of symptomatic hematomas (P = .34) or mammographically evident hematomas (P = .53) after 12- to 14-gauge US-guided CNBBs performed with epinephrine-containing lidocaine vs lidocaine alone. Fewer symptomatic hematomas occurred after 9-gauge CNBBs in the epinephrine-containing lidocaine group (0.6%; 2/310) compared with the lidocaine alone (4.1%; 8/194) (P = .02). After 9-gauge CNBBs, mammographically evident hematomas were less frequent (16.1% vs 41.2%; P <.0001) with epinephrine-containing lidocaine compared with lidocaine alone. Conclusion: Epinephrine-containing lidocaine reduced rates of symptomatic and mammographically detected hematomas after 9-gauge CNBBs. Local infiltration with epinephrine-containing lidocaine could be considered in 9-gauge CNBBs to reduce hematoma risk.
- 30 August 2025
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 7 (6) , 653-663
Open AccessEpinephrine-Containing Lidocaine and Hematoma Risk After Image-Guided Core-Needle Breast Biopsy
Objective: To evaluate the risk of symptomatic hematomas in patients receiving epinephrine-containing lidocaine compared with lidocaine alone after core-needle breast biopsies (CNBBs). The efficacy of epinephrine-containing lidocaine in reducing hematoma risk following image-guided CNBB remains unclear. Methods: A single-institution, retrospective review of all CNBBs performed during a 6-month period using lidocaine alone (September 1, 2022, to March 15, 2023) due to a national shortage of epinephrine-containing lidocaine and a 6-month period using epinephrine-containing lidocaine (April 1, 2023, to October 1, 2023). A nurse navigator contacted all patients postbiopsy to assess postprocedural complications, including symptomatic hematomas. Postprocedure mammograms were reviewed for detectable hematomas after 9-gauge and 12- to 14-gauge CNBBs. Logistic regression models evaluated the associations between epinephrine-containing lidocaine use and symptomatic and mammographically evident hematomas. Results: A total of 1157 CNBBs were performed in 967 patients; 619 received epinephrine-containing lidocaine and 538 received lidocaine alone. There were 11 (1.0%; 11/1157) symptomatic hematomas, 10 of which occurred following 9-gauge CNBBs (6 with stereotactic/tomosynthesis guidance and 4 with MRI guidance). There was no significant difference in the occurrence of symptomatic hematomas (P = .34) or mammographically evident hematomas (P = .53) after 12- to 14-gauge US-guided CNBBs performed with epinephrine-containing lidocaine vs lidocaine alone. Fewer symptomatic hematomas occurred after 9-gauge CNBBs in the epinephrine-containing lidocaine group (0.6%; 2/310) compared with the lidocaine alone (4.1%; 8/194) (P = .02). After 9-gauge CNBBs, mammographically evident hematomas were less frequent (16.1% vs 41.2%; P <.0001) with epinephrine-containing lidocaine compared with lidocaine alone. Conclusion: Epinephrine-containing lidocaine reduced rates of symptomatic and mammographically detected hematomas after 9-gauge CNBBs. Local infiltration with epinephrine-containing lidocaine could be considered in 9-gauge CNBBs to reduce hematoma risk.
- 7 July 2025
- Published by Elsevier in Clinical Imaging
- Vol. 125, 110559
Global radiology: Building equitable and effective partnerships with low and middle-income countries
- 7 July 2025
- Published by Elsevier in Clinical Imaging
- Vol. 125, 110559
Global radiology: Building equitable and effective partnerships with low and middle-income countries
- 17 November 2024
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (2) , 211-219
Multi-Institutional Evaluation and Training of Breast Density Classification AI Algorithm Using ACR Connect and AI-LAB
- 17 November 2024
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (2) , 211-219
Multi-Institutional Evaluation and Training of Breast Density Classification AI Algorithm Using ACR Connect and AI-LAB
- 1 June 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 311 (3) , e241124
Clinical Implementation of AI in Screening Mammography: The Essential Role of Prospective Evaluation
- 1 June 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 311 (3) , e241124
Clinical Implementation of AI in Screening Mammography: The Essential Role of Prospective Evaluation
- 17 May 2024
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 6 (4) , 430-448
Forget Me Not: Incidental Findings on Breast MRI
With the growing utilization and expanding role of breast MRI, breast imaging radiologists may encounter an increasing number of incidental findings beyond the breast and axilla. Breast MRI encompasses a large area of anatomic coverage extending from the lower neck to the upper abdomen. While most incidental findings on breast MRI are benign, identifying metastatic disease can have a substantial impact on staging, prognosis, and treatment. Breast imaging radiologists should be familiar with common sites, MRI features, and breast cancer subtypes associated with metastatic disease to assist in differentiating malignant from benign findings. Furthermore, detection of malignancies of nonbreast origin as well as nonmalignant, but clinically relevant, incidental findings can significantly impact clinical management and patient outcomes. Breast imaging radiologists should consistently follow a comprehensive search pattern and employ techniques to improve the detection of these important incidental findings.
- 17 May 2024
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 6 (4) , 430-448
Forget Me Not: Incidental Findings on Breast MRI
With the growing utilization and expanding role of breast MRI, breast imaging radiologists may encounter an increasing number of incidental findings beyond the breast and axilla. Breast MRI encompasses a large area of anatomic coverage extending from the lower neck to the upper abdomen. While most incidental findings on breast MRI are benign, identifying metastatic disease can have a substantial impact on staging, prognosis, and treatment. Breast imaging radiologists should be familiar with common sites, MRI features, and breast cancer subtypes associated with metastatic disease to assist in differentiating malignant from benign findings. Furthermore, detection of malignancies of nonbreast origin as well as nonmalignant, but clinically relevant, incidental findings can significantly impact clinical management and patient outcomes. Breast imaging radiologists should consistently follow a comprehensive search pattern and employ techniques to improve the detection of these important incidental findings.
- 8 March 2024
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 6 (3) , 330-331
Ectopic Abdominal Breast Tissue
A 23-year-old woman presented to the emergency department with lower abdominal pain and a lump. She reported a history of similar but milder intermittent symptoms over the past 5 months. The symptoms were cyclical with her monthly menstrual cycle and most pronounced prior to her period. Pelvic ultrasound (not shown) was unremarkable, with normal appearance of the ovaries and uterus. Due to the severity of the pain, a CT of the abdomen was performed. The CT findings were consistent with bilateral infraumbilical abdominal accessory breast tissue ( Figure 1) corresponding to the site of the patient's symptoms. The patient was subsequently referred to the outpatient breast surgical clinic, where the provider palpated what felt like normal breast tissue with no suspicious clinical findings at the site of the patient's symptoms. Accessory breast tissue, also known as ectopic breast tissue, can occur anywhere along the embryologic mammary streak or milk line, which extends bilaterally from the axilla to the anterior chest, upper abdomen ( Figure 2), lower abdomen, and inguinal region. It occurs when residual mammary tissue anywhere along this line fails to regress during embryonic development. It is most commonly seen in the axillary and inframammary fold regions. The imaging appearance is similar to that of fibroglandular tissue in the normal breasts. Treatment is usually not warranted, but excision may be considered for symptomatic relief of large volume accessory tissue. Although very rare, primary breast cancers have been reported in accessory tissue. Therefore, any suspicious masses or other findings within the accessory tissue should undergo diagnostic workup to exclude an underlying malignancy.
- 8 March 2024
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 6 (3) , 330-331
Ectopic Abdominal Breast Tissue
A 23-year-old woman presented to the emergency department with lower abdominal pain and a lump. She reported a history of similar but milder intermittent symptoms over the past 5 months. The symptoms were cyclical with her monthly menstrual cycle and most pronounced prior to her period. Pelvic ultrasound (not shown) was unremarkable, with normal appearance of the ovaries and uterus. Due to the severity of the pain, a CT of the abdomen was performed. The CT findings were consistent with bilateral infraumbilical abdominal accessory breast tissue ( Figure 1) corresponding to the site of the patient's symptoms. The patient was subsequently referred to the outpatient breast surgical clinic, where the provider palpated what felt like normal breast tissue with no suspicious clinical findings at the site of the patient's symptoms. Accessory breast tissue, also known as ectopic breast tissue, can occur anywhere along the embryologic mammary streak or milk line, which extends bilaterally from the axilla to the anterior chest, upper abdomen ( Figure 2), lower abdomen, and inguinal region. It occurs when residual mammary tissue anywhere along this line fails to regress during embryonic development. It is most commonly seen in the axillary and inframammary fold regions. The imaging appearance is similar to that of fibroglandular tissue in the normal breasts. Treatment is usually not warranted, but excision may be considered for symptomatic relief of large volume accessory tissue. Although very rare, primary breast cancers have been reported in accessory tissue. Therefore, any suspicious masses or other findings within the accessory tissue should undergo diagnostic workup to exclude an underlying malignancy.
- 1 February 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (2) , e230129
MRI of the Lactating Breast
The breasts undergo marked physiologic changes during lactation that can make conventional imaging evaluation with mammography and US challenging. MRI can be a valuable diagnostic aid to differentiate physiologic and benign processes from malignancy in patients who are lactating. In addition, MRI may allow more accurate delineation of disease involvement than does conventional imaging and assists in locoregional staging, screening of the contralateral breast, assessment of response to neoadjuvant chemotherapy, and surgical planning. Although the American College of Radiology recommends against patients undergoing contrast-enhanced MRI during pregnancy because of fetal safety concerns, contrast-enhanced MRI is safe during lactation. As more women delay childbearing, the incidence of pregnancy-associated breast cancer (PABC) and breast cancer in lactating women beyond the 1st year after pregnancy is increasing. Thus, MRI is increasingly being performed in lactating women for diagnostic evaluation and screening of patients at high risk. PABC is associated with a worse prognosis than that of non-PABCs, with delays in diagnosis contributing to an increased likelihood of advanced-stage disease at diagnosis. Familiarity with the MRI features of the lactating breast and the appearance of various pathologic conditions is essential to avoid diagnostic pitfalls and prevent delays in cancer diagnosis and treatment. The authors review clinical indications for breast MRI during lactation, describe characteristic features of the lactating breast at MRI, and compare MRI features of a spectrum of benign and malignant breast abnormalities. ©RSNA, 2024 Test Your Knowledge questions for this article are available in the supplemental material. See the invited commentary by Chikarmane in this issue.
- 1 February 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (2) , e230129
MRI of the Lactating Breast
The breasts undergo marked physiologic changes during lactation that can make conventional imaging evaluation with mammography and US challenging. MRI can be a valuable diagnostic aid to differentiate physiologic and benign processes from malignancy in patients who are lactating. In addition, MRI may allow more accurate delineation of disease involvement than does conventional imaging and assists in locoregional staging, screening of the contralateral breast, assessment of response to neoadjuvant chemotherapy, and surgical planning. Although the American College of Radiology recommends against patients undergoing contrast-enhanced MRI during pregnancy because of fetal safety concerns, contrast-enhanced MRI is safe during lactation. As more women delay childbearing, the incidence of pregnancy-associated breast cancer (PABC) and breast cancer in lactating women beyond the 1st year after pregnancy is increasing. Thus, MRI is increasingly being performed in lactating women for diagnostic evaluation and screening of patients at high risk. PABC is associated with a worse prognosis than that of non-PABCs, with delays in diagnosis contributing to an increased likelihood of advanced-stage disease at diagnosis. Familiarity with the MRI features of the lactating breast and the appearance of various pathologic conditions is essential to avoid diagnostic pitfalls and prevent delays in cancer diagnosis and treatment. The authors review clinical indications for breast MRI during lactation, describe characteristic features of the lactating breast at MRI, and compare MRI features of a spectrum of benign and malignant breast abnormalities. ©RSNA, 2024 Test Your Knowledge questions for this article are available in the supplemental material. See the invited commentary by Chikarmane in this issue.
- 8 January 2024
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 6 (3) , 232-237
Prevalent vs Incident Screen: Why Does It Matter?
There are important differences in the performance and outcomes of breast cancer screening in the prevalent compared to the incident screening rounds. The prevalent screen is the first screening examination using a particular imaging technique and identifies pre-existing, undiagnosed cancers in the population. The incident screen is any subsequent screening examination using that technique. It is expected to identify fewer cancers than the prevalent screen because it captures only those cancers that have become detectable since the prior screening examination. The higher cancer detection rate at prevalent relative to incident screening should be taken into account when analyzing the medical audit and effectiveness of new screening technologies.
- 8 January 2024
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 6 (3) , 232-237
Prevalent vs Incident Screen: Why Does It Matter?
There are important differences in the performance and outcomes of breast cancer screening in the prevalent compared to the incident screening rounds. The prevalent screen is the first screening examination using a particular imaging technique and identifies pre-existing, undiagnosed cancers in the population. The incident screen is any subsequent screening examination using that technique. It is expected to identify fewer cancers than the prevalent screen because it captures only those cancers that have become detectable since the prior screening examination. The higher cancer detection rate at prevalent relative to incident screening should be taken into account when analyzing the medical audit and effectiveness of new screening technologies.
- 15 December 2023
- Published by Elsevier in Clinical Imaging
- Vol. 106, 110062
The role of digital mammographic surveillance for detection of asymptomatic recurrence in autologous flap reconstructions
- 15 December 2023
- Published by Elsevier in Clinical Imaging
- Vol. 106, 110062
The role of digital mammographic surveillance for detection of asymptomatic recurrence in autologous flap reconstructions
- Open Access
- 9 November 2023
- Published by Elsevier in The Breast
- Vol. 71, S57
PO121 A COMPARISON OF CLINICOPATHOLOGICAL FEATURES AND PROGNOSIS BETWEEN TRIPLE-NEGATIVE AND NON-TRIPLE NEGATIVE BREAST CANCER AT OCEAN ROAD CANCER INSTITUTE
- 9 November 2023
- Published by Elsevier in The Breast
- Vol. 71, S57
Open AccessPO121 A COMPARISON OF CLINICOPATHOLOGICAL FEATURES AND PROGNOSIS BETWEEN TRIPLE-NEGATIVE AND NON-TRIPLE NEGATIVE BREAST CANCER AT OCEAN ROAD CANCER INSTITUTE